HomeFilePeripheral vascular disease

Peripheral vascular disease

Sirolimus-Eluting Balloon in Femoropopliteal Disease

Drug-eluting balloons (DEB) with paclitaxel have shown efficacy and safety in the treatment of femoropopliteal disease. Sirolimus-eluting...

Catheter-Based Therapy for Pulmonary Embolism: Lower Mortality and Rehospitalization?

Venous thromboembolism represents one of the main causes of cardiovascular death. Pulmonary embolism (PE) can vary from...

Carotid Endarterectomy vs. Carotid Angioplasty in Symptomatic and Asymptomatic Patients: 30-Day Outcomes

Extracranial carotid artery disease represents 15 to 20% of all strokes. Carotid revascularization plays a role in...

Drug-Coated Balloon Angioplasty in Femoropopliteal CTOs: Intraluminal or Subintimal?

Patients with peripheral vascular disease often experience femoropopliteal compromise. It is estimated that approximately 50% of lesions...

Peripheral Vascular Disease: Our Reality in Latin America, with the LATAM SOLACI Peripheral Registry

On the one hand, chronic peripheral vascular disease is on the rise. On the other, over the...

ACC 2024 | IVUS-DCB

Drug-coated balloons (DCB) have proven to be effective in the treatment of femoropopliteal pathology, although they entail...

IN.PACT Outcomes at 5 Years

Over time, percutaneous coronary intervention (PCI) with drug coated balloons (DCB) have been shown more beneficial than...

Treatment of Femoropopliteal Lesions with Low-Dose vs. High-Dose Drug-Coated Balloons

The use of drug-covered balloons (DCBs) has increased significantly for the endovascular treatment of femoropopliteal arterial disease....